Revisiting the hERG safety margin after 20 years of routine hERG screening.

Leishman, Derek J; Abernathy, Matthew M; Wang, Evan B

Revisiting the hERG safety margin after 20 years of routine hERG screening.

Leishman, Derek J; Abernathy, Matthew M; Wang, Evan B.

Affiliation

Leishman DJ; Drug Disposition, Toxicology and PKPD, Eli Lilly and Company, Indianapolis, IN 46285, USA. Electronic address: derek.leishman@lilly.com.
Abernathy MM; Drug Disposition, Toxicology and PKPD, Eli Lilly and Company, Indianapolis, IN 46285, USA.
Wang EB; Drug Disposition, Toxicology and PKPD, Eli Lilly and Company, Indianapolis, IN 46285, USA.

J Pharmacol Toxicol Methods ; 105: 106900, 2020 Sep.

Article in En | MEDLINE | ID: mdl-32768644

Subject(s)

Cardiotoxicity/etiology; Cardiotoxicity/metabolism; ERG1 Potassium Channel/antagonists & inhibitors; Arrhythmias, Cardiac/chemically induced; Arrhythmias, Cardiac/metabolism; Electrocardiography/methods; Humans; Long QT Syndrome/chemically induced; Long QT Syndrome/metabolism; Torsades de Pointes/chemically induced; Torsades de Pointes/metabolism

Key words

QTc; Safety margin; Torsade de pointes; hERG

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Cardiotoxicity / ERG1 Potassium Channel Type of study: Diagnostic_studies / Guideline / Prognostic_studies / Screening_studies Limits: Humans Language: En Journal: J Pharmacol Toxicol Methods Journal subject: FARMACOLOGIA / TOXICOLOGIA Year: 2020 Document type: Article Country of publication: United States

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google